---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-088069"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-08T00:12:00.836232+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Virpax receives Nasdaq deficiency notice for delayed Q3 10-Q filing; 60 days to submit plan

## Summary
- Nasdaq notified Virpax on Nov 16, 2023 for non-compliance due to late Q3 10-Q filing.
- Delay stems from evaluating Delaware court decision in litigation with Sorrento Therapeutics and Scilex Pharmaceuticals.
- Company has until Jan 16, 2024 to submit a plan; Nasdaq can extend to May 13, 2024.
- Listing unaffected immediately; no guarantee of regaining compliance.

## SEC filing metadata
- accession: 0001213900-23-088069
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000121390023088069/0001213900-23-088069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000121390023088069/ea188634-8k_virpaxpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-088069
- JSON: https://secwatch.observer/filing/0001213900-23-088069.json
- Plain text: https://secwatch.observer/filing/0001213900-23-088069.txt

## Key facts
- Listing & Compliance Notices
  Virpax Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: November 16, 2023, the Company received a letter from The NASDAQ Stock Market LLC (“NASDAQ”) notifying the Company that it was not in compliance with the continued listing requirements of NASDAQ Listing Rule 5250(c)(1) because its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 had not yet been filed with the Securities and Exchange Commission (“SEC”). NASDAQ Listing Rule 5250(c)(1) requires the Company to timely file all required periodic financial reports with the SEC. Under the Nasdaq rules, the Company now has 60 calendar days (until January 16, 2024) to submit a pl
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390023088069/0001213900-23-088069-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.